Pathophysiological changes at single and multiple introduction of Ciprofloxacin solution under experimental conditions
Abstract
The article presents the results of experimental biological modelling of single and subacute introduction of Ciprofloxacin to the rabbits. State of an organism of animals was estimated by biochemical, hematological, hemostatic and morphologic indices. Introduction of preparation samples was intravenous, according to the Instruction of medical use. Main result of the experiments is determination of toxic effects that are typical for fluorinequinolone and developed on the background of multiple introduction of preparation in the doses higher than therapeutic.
About the Authors
A. G. Yushkov
Scientific Center of Reconstructive and Restorative Surgery SB RAMS
Russian Federation
Russian Federation
M. M. Rasulov
State Research Institute for Chemistry and Technology of Organoelement Compounds
Russian Federation
Russian Federation
P. A. Storozhenko
State Research Institute for Chemistry and Technology of Organoelement Compounds
Russian Federation
Russian Federation
G. G. Yushkov
Angarsk State Technical Academy
Russian Federation
Russian Federation
N. A. Shulgina
Angarsk State Technical Academy
Russian Federation
Russian Federation
A. A. Gushchina
Angarsk State Technical Academy
Russian Federation
Russian Federation
References
1. Бурбелло А.Т., Шабров А.В., Денисенко П.П. Современные лекарственные средства. - СПб.: Изд-во «Нева», 2006. - С. 97-98.
2. Капранов Н.И., Шабалова А.А., Смиронова У.Ю. и др. Применение Ципрофлоксацина у детей с муко-висцидозом // Клинич. фармакология и терапия. -1994. - № 2. - С. 40-41.
3. Карпов О.И. Проблема кардиотоксичности фторхинолонов в клинической практике // Лечащий врач. - 2006. - № 2. - С. 453.
4. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ / Под общей редакцией Р.У Хабриева; 2-е изд-е, перераб. и доп. - М.: ОАА «Медицина», 2005. - 832 с.
5. Ципрофлоксацин. К 10-летию опыта мирового клинического применения антибиотика ципробай (Ципрофлоксацин) фирмы Байер, серия публикаций // Антибиотики и химиотерапия. - 1997. -Вып. 42 (6). - С. 3-48.
6. Шлютер Г. Потенциальные токсикологические эффекты Ципрофлоксацина // Достижения антибиотикотерапии. Ципрофлоксацин. Симпозиум. - М., 1989. - С. 35-37.
7. Lipsky B.A., Baker C.A. Fluoroquilone toxicity profiles. A review focusing on newer agents // Clin. Infect. Dis. - 1999. - Vol. 28, N 2. - P. 352-364.
8. Mandell L.A., Ball P. Tillotson G. Antimicrobial safety and tolerability: differences and dilemmas // Clin. Infect. Dis. - 2001. - Vol. 32, N 1. - P. 72-79
9. Thomas R.J. Neurotoxicity of antibacterial therapy // South. Med. J. - 1994. - Vol. 87. - P. 869-874.
10. Prabhakar M., Krahn A.D. Ciprofloxacin-induced acquired long QT syndrome // Heart Rhythm. - 2004. -Vol. 1,N5.- P. 624-(52(5.
Review
For citations:
Yushkov A.G., Rasulov M.M., Storozhenko P.A., Yushkov G.G., Shulgina N.A., Gushchina A.A. Pathophysiological changes at single and multiple introduction of Ciprofloxacin solution under experimental conditions. Acta Biomedica Scientifica. 2013;(5):167-171. (In Russ.)
Views:
339
Email this article 
